Treatment of Desmoid Fibromatosis With Arterial Embolization

Summary

Desmoid fibromatoses are rare and locally aggressive mesenchymal tumors. The current scientific evidence regarding the efficacy and safety of the treatment of desmoid fibromatosis by arterial embolization is constituted by several retrospective and prospective studies. These studies report promising results through the use of chemoembolization, that is, arterial embolization using particles loaded with chemotherapy. Instead, the type of treatment we propose would consist of injection of embolizing material without the use of chemotherapy, based on the positive results we have consistently reported over the years on arterial embolization of musculoskeletal tumors.

Eligibility

Inclusion Criteria:

* Patients of both sexes aged ≥ 12 years
* Fibromatosis demsoid symptomatic and in active phase (documented growth at last follow-ups)
* Patients not eligible for surgery or cryoablation
* Patients who have had embolization surgery for fibromatosis desmoide from 01/01/2023 to date and all new patients listed for this type of treatment.
* Signature of informed consent to the study

Exclusion Criteria:

* Patients with life expectancy \<3 months or severely impaired status functional status (ASA 4)
* Patients with fibromatosis not in active phase, documented clinically and by investigations imaging (MRI, CT)
* Patients with coagulation deficiency or plateletopenic disease
* Patients with documented active infection
* Incompatibility to performing MRI examination.

Conditions2

Browse More Trials